These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 513484

  • 1. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
    Fournier A, Bordier P, Gueris J, Sebert JL, Marie P, Ferrière C, Bedrossian J, DeLuca HF.
    Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
    [No Abstract] [Full Text] [Related]

  • 2. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Junor BJ, Catto GR, Macleod M.
    Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512
    [No Abstract] [Full Text] [Related]

  • 3. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
    Fournier AE, Bordier PJ, Gueris J, Chanard J, Marie P, Ferriere C, Osario M, Bedrossian J, De Luca HF.
    Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients].
    Sebert JL, Marie A, Kuntz D, Marie P, Gueris J, Smadja A, Fournier A, Quichaud J.
    Rev Rhum Mal Osteoartic; 1981 Aug; 48(7-9):535-41. PubMed ID: 7291931
    [Abstract] [Full Text] [Related]

  • 6. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG, Goldstein DA, Malluche HH.
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 1-alpha-hydroxycholecalciferol for renal osteodystrophy.
    Brownjohn AM, Goodwin FJ, Hately W, Marsh FP, O'Riordan JL, Papapoulos SE.
    Br Med J; 1977 Sep 17; 2(6089):721-3. PubMed ID: 912269
    [Abstract] [Full Text] [Related]

  • 9. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol.
    Bordier PJ, Marie PJ, Arnaud CD.
    Kidney Int Suppl; 1975 Jan 17; (2):102-12. PubMed ID: 1057669
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Renal osteodystrophy in two children : a comparison of the effects of 1 alpha-hydroxycholecalciferol (author's transl)].
    Chantraine JM, Davin JC, Lambrechts L, Heynen G.
    Ann Endocrinol (Paris); 1979 Jan 17; 40(2):161-2. PubMed ID: 475307
    [Abstract] [Full Text] [Related]

  • 14. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
    Henderson RG, Russell RG, Ledingham JG, Smith R, Oliver DO, Walton RJ, Small DG, Preston C, Warner GT.
    Lancet; 1974 Mar 09; 1(7854):379-84. PubMed ID: 4131033
    [No Abstract] [Full Text] [Related]

  • 15. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE, Bordier PJ, Gueris J, Chanard J, Marie P, Ferriere C, Osario M, Bedrossian J, de Luca HF.
    Proc Eur Dial Transplant Assoc; 1976 Mar 09; 12():227-36. PubMed ID: 935115
    [Abstract] [Full Text] [Related]

  • 16. 1alpha-hydroxychloecalciferol treatment of long-term hemodialyzed patients. Effects on mineral metabolism, bone mineral content and bone morphometry.
    Nielsen HE, Melsen F, Christensen MS, Hansen HE, Rodbro P, Johannsen A.
    Clin Nephrol; 1977 Oct 09; 8(4):429-34. PubMed ID: 923161
    [No Abstract] [Full Text] [Related]

  • 17. Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.
    Kanis JA, Henderson RG, Heynen G, Ledingham JG, Russell RG, Smith R, Walton RJ.
    Arch Dis Child; 1977 Jun 09; 52(6):473-81. PubMed ID: 879833
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.